Triple-drug attack shows promise against hard-to-treat bile duct cancer

NCT ID NCT05668884

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jan 26, 2026 · Last updated May 15, 2026 · Updated 12 times

Summary

This study tests a combination of three drugs—chemotherapy (GEMOX), a targeted therapy (donafenib), and an immunotherapy (tislelizumab)—in people with advanced biliary tract cancer that has spread. The goal is to see if this mix shrinks tumors and improves survival. About 93 adults aged 18 to 75 with stage III or IV disease will take part. This is an early-phase trial, so the main focus is safety and how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200062, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

BILIARY TRACT CARCINOMA